{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:32:21Z","timestamp":1794472341236,"version":"4.9.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.vaccine.2024.01.057","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T23:35:35Z","timestamp":1705880135000},"page":"1116-1121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A rabies mRNA vaccine with H270P mutation in its glycoprotein induces strong cellular and humoral immunity"],"prefix":"10.1016","volume":"42","author":[{"given":"Han","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangyang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunbao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.01.057_b0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrmicro.2018.11","article-title":"The spread and evolution of rabies virus: conquering new frontiers","volume":"16","author":"Fisher","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2024.01.057_b0010","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abp9151","article-title":"Structure of the rabies virus glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"8","author":"Callaway","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2024.01.057_b0015","article-title":"A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice","volume":"13","author":"Bai","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.01.057_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2022.07.014","article-title":"Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies","volume":"30","author":"Ng","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2024.01.057_b0025","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1128\/jvi.65.9.4853-4859.1991","article-title":"Reversible conformational changes and fusion activity of rabies virus glycoprotein","volume":"65","author":"Gaudin","year":"1991","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.01.057_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2019.12.012","article-title":"Structural Analysis of Rabies Virus Glycoprotein Reveals pH-Dependent Conformational Changes and Interactions with a Neutralizing Antibody","volume":"27","author":"Yang","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2024.01.057_b0035","doi-asserted-by":"crossref","first-page":"A140","DOI":"10.1016\/j.vaccine.2018.08.039","article-title":"New human rabies vaccines in the pipeline","volume":"37","author":"Fooks","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.057_b0040","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2024.01.057_b0045","first-page":"1","article-title":"mRNA-Based Vaccines and Mode of Action","volume":"440","author":"Gergen","year":"2022","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2024.01.057_b0050","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.7150\/thno.53691","article-title":"The 2020 race towards SARS-CoV-2 specific vaccines","volume":"11","author":"Karpinski","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.vaccine.2024.01.057_b0055","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2024.01.057_b0060","article-title":"Effects of Varicella-Zoster Virus Glycoprotein E Carboxyl-Terminal Mutation on mRNA Vaccine Efficacy","volume":"9","author":"Cao","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.01.057_b0065","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12250-013-3321-x","article-title":"Establishment and preliminary application of a rapid fluorescent focus inhibition test (RFFIT) for rabies virus","volume":"28","author":"Yu","year":"2013","journal-title":"Virol Sin"},{"key":"10.1016\/j.vaccine.2024.01.057_b0070","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jviromet.2005.05.005","article-title":"Rapid human metapneumovirus microneutralization assay based on green fluorescent protein expression","volume":"128","author":"Biacchesi","year":"2005","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2024.01.057_b0075","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-bioeng-110220-031722","article-title":"Current Developments and Challenges of mRNA Vaccines","volume":"24","author":"Chen","year":"2022","journal-title":"Annu Rev Biomed Eng"},{"key":"10.1016\/j.vaccine.2024.01.057_b0080","doi-asserted-by":"crossref","first-page":"2270081","DOI":"10.1080\/22221751.2023.2270081","article-title":"A single immunization with core-shell structured lipopolyplex mRNA vaccine against rabies induces potent humoral immunity in mice and dogs","volume":"12","author":"Wan","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2024.01.057_b0085","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12985-022-01919-7","article-title":"An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs","volume":"19","author":"Li","year":"2022","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2024.01.057_b0090","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.01.057_b0095","article-title":"Advances in RNA Vaccines for Preventive Indications: A Case Study of A Vaccine Against Rabies","volume":"7","author":"Armbruster","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.01.057_b0100","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41467-020-14398-7","article-title":"Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein","volume":"11","author":"Hellert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.01.057_b0105","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41541-022-00591-w","article-title":"RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses","volume":"7","author":"Su","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2024.01.057_b0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade0424","article-title":"A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine","volume":"14","author":"Chang","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2024.01.057_b0115","doi-asserted-by":"crossref","first-page":"13396","DOI":"10.1128\/JVI.01962-14","article-title":"Characterization of pH-sensitive molecular switches that trigger the structural transition of vesicular stomatitis virus glycoprotein from the postfusion state toward the prefusion state","volume":"88","author":"Ferlin","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.01.057_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1186063","article-title":"Antiviral mechanisms of two broad-spectrum monoclonal antibodies for rabies prophylaxis and therapy","volume":"14","author":"Zorzan","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.01.057_b0125","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.4049\/jimmunol.1601444","article-title":"Type 1 Immune Mechanisms Driven by the Response to Infection with Attenuated Rabies Virus Result in Changes in the Immune Bias of the Tumor Microenvironment and Necrosis of Mouse GL261 Brain Tumors","volume":"198","author":"Bongiorno","year":"2017","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:33:36Z","timestamp":1759404816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24000690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0264410X24000690"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A rabies mRNA vaccine with H270P mutation in its glycoprotein induces strong cellular and humoral immunity","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}